SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon concludes 10% stake sale in Syngene

13 Jan 2015 Evaluate

Biocon has completed sale of 10% stake in its research arm Syngene for Rs 380 crore to IVF Trustee Company. In September, the company had announced that Mauritius-based private equity fund Silver Leaf Oak would acquire 10% stake in its research services arm Syngene International for Rs 380 crore from Biocon Research (BRL), a wholly-owned subsidiary of the Bangalore-based firm.

The deal had put the entire valuation of Syngene International, a wholly-owned subsidiary of Biocon, at Rs 3,800 crore.

Biocon is India’s largest and Asia’s leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

 

Biocon Share Price

361.40 2.90 (0.81%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×